Found 553 clinical trials
Post-Authorization Safety Study (PASS) of LysaKare in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study is to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels will be performed during infusion and up to 24 hours post start of infusion compared to baseline.
- 0 views
- 08 Sep, 2021
- 10 locations
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).
To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532. The MTDs will be defined based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period in studied regimens. The RDE will …
- 0 views
- 18 Sep, 2021
- 6 locations
Nivolumab +/- Ipilimumab in Patients With Advanced Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
Neuroendocrine tumors of the lung include the small cell carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC) and represent 20% of lung cancer. One of the only studies reported to
- 30 views
- 26 Jan, 2021
- 8 locations
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium
- 17 views
- 22 Apr, 2021
- 1 location
Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor
Midgut neuroendocrine tumours present an increasing incidence and poor survival at 5 years with limited therapeutic options for metastatic, non-operable cases. Lu-177 Dotatate, targeting
- 0 views
- 26 Jan, 2021
Study to Assess the Efficacy and Safety of Lanreotide Autogel in Chinese Participants With GEP-NETs
This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs. The study will include a screening period of up to 4 weeks followed by a 48-week intervention period. After completion …
- 0 views
- 05 Aug, 2021
- 13 locations
Study of PRRT in Metastatic World Health Organization (WHO) Grade 1 or 2 SSTR Positive GEP-NET Who Are Candidates for Cytoreductive Surgery
SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.
- 0 views
- 27 Apr, 2021
- 1 location
Cabozantinib in High Grade Neuroendocrine Neoplasms
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately
- 0 views
- 05 Feb, 2021
- 1 location
MIBG Therapy for Patients With MIBG Avid Tumors
radiopharmaceutical that concentrates within adrenomedullary tissue. The agent was initially used for tumor imaging due to its capability to locate pheochromocytomas, neuroblastomas and other neuroendocrine tumors
- 2 views
- 03 Jun, 2021
- 1 location
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Cisplatin and Etoposide is the standard of care in NEC originating from the gastro-intestinal tract and lung, based on retrospective studies. Nevertheless the prognosis of this group of patients is still poor with median survival of less than 20 months. Everolimus is an mammilian target of rapamycin (mTOR) inhibitor that …
- 0 views
- 23 Jan, 2021
- 5 locations